

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/M9635D8FE3CEN.html>

Date: September 2018

Pages: 66

Price: US\$ 3,500.00 (Single User License)

ID: M9635D8FE3CEN

Abstracts

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2018

SUMMARY

Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake.

Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 1 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively.

Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Genetic Disorders, Musculoskeletal Disorders, Infectious Disease and Women's Health which include indications Obesity, Type 2 Diabetes, Alphavirus Infections, Amyotrophic Lateral Sclerosis, Cachexia, Female Hypoactive Sexual Desire Disorder, Gouty Arthritis (Gout), Infantile Spasm (West Syndrome), Lipodystrophy (Lipoatrophy), Metabolic Syndrome, Multiple Sclerosis and Prader-Willi Syndrome (PWS).

The latest report Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2018, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted

therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)

The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects

The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Melanocortin Receptor 4

(MC4R) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Melanocortin Receptor 4 (MC4R) - Overview

Melanocortin Receptor 4 (MC4R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development

Mallinckrodt Plc

Palatin Technologies Inc

Rhythm Pharmaceuticals Inc

Melanocortin Receptor 4 (MC4R) - Drug Profiles

(liraglutide + setmelanotide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQB-565 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bremelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8905 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize MC4-R for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize MC4R for Genetic Disorders and Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanocortin Receptor 4 (MC4R) - Dormant Products

Melanocortin Receptor 4 (MC4R) - Discontinued Products

Melanocortin Receptor 4 (MC4R) - Product Development Milestones

Featured News & Press Releases

Jul 23, 2018: Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity

Jun 28, 2018: Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection) Achieves its Enrollment Target

Jun 18, 2018: Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity

Jun 18, 2018: Mallinckrodt Reports Interim Findings Of H.P. Acthar Gel (Repository Corticotropin Injection) Studies

Jun 16, 2018: Mallinckrodt Presents Preliminary Interim Findings of Rheumatoid

Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection)

Jun 14, 2018: Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing

Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity

Jun 04, 2018: AMAG Pharmaceuticals Announces FDA Acceptance of New Drug

Application Filing for Bremelanotide

Jun 04, 2018: Palatin Technologies Announces FDA Acceptance for Review of

Bremelanotide NDA

Jun 01, 2018: Mallinckrodt Presents Interim Findings of Multiple Sclerosis Relapse

Registry for H.P. Acthar Gel

May 09, 2018: Rhythm Pharmaceuticals Announces Nature Medicine Publication of

Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR

Deficiency Obesity

May 07, 2018: Mallinckrodt Provides Facts on H.P. Acthar Gel

Mar 28, 2018: MNK H.P. Acthar Gel CHART Trial Results Alert

Mar 26, 2018: AMAG Pharmaceuticals Submits a New Drug Application to the U.S.

Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual

Desire Disorder in Premenopausal Women

Mar 19, 2018: Rhythm Pharmaceuticals Announces Presentation of Genetic

Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018

Jan 30, 2018: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel

(Repository Corticotropin Injection) for Pulmonary Sarcoidosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Mallinckrodt Plc, H2 2018
Pipeline by Palatin Technologies Inc, H2 2018
Pipeline by Rhythm Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Mallinckrodt Plc

Palatin Technologies Inc

Rhythm Pharmaceuticals Inc

I would like to order

Product name: Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/M9635D8FE3CEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M9635D8FE3CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970